 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...125126127128129130131132133134135...143144» |
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Dec 5, 2014
P3, N=466, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Metastases: A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=20, Completed, Sponsor: Emory University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=48 --> 20
- ||||| Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial: Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 24, 2014
P1/2, N=62, Not yet recruiting, Sponsor: Julie E. Bauman, MD, MPH
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer (clinicaltrials.gov) - Nov 23, 2014
P2, N=53, Completed, Sponsor: Centre Antoine Lacassagne
Active, not recruiting --> Completed | N=48 --> 20 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (clinicaltrials.gov) - Nov 20, 2014
P2, N=27, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: MACBETH: Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (clinicaltrials.gov) - Nov 20, 2014
P2, N=106, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) (clinicaltrials.gov) - Nov 18, 2014
P2, N=150, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Study in Advanced Solid Tumors (clinicaltrials.gov) - Nov 17, 2014
P2, N=8, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2016 N=15 --> 8
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial initiation date, Metastases: A Study in Advanced Solid Tumors (clinicaltrials.gov) - Nov 17, 2014
P2, N=8, Recruiting, Sponsor: Eli Lilly and Company
N=15 --> 8 N=15 --> 8 | Initiation date: Mar 2010 --> Jun 2010
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Surgery, Metastases: BOND-3: Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 17, 2014
P2, N=120, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 17, 2014
P2, N=78, Recruiting, Sponsor: Southwest Oncology Group
N=15 --> 8 | Initiation date: Mar 2010 --> Jun 2010 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Feb 2017 --> Jun 2017
- ||||| Biomarker, New P2 trial, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Nov 14, 2014
P2, N=1680, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Nov 12, 2014
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Feb 2017 --> Jun 2017 Trial primary completion date: Jun 2016 --> Oct 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer (clinicaltrials.gov) - Nov 12, 2014
P2, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2016 --> Oct 2017 Recruiting --> Completed | N=66 --> 50 | Trial primary completion date: Nov 2015 --> Nov 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: EMR 062202-514: An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=133, Terminated, Sponsor: Merck KGaA
Recruiting --> Completed | N=66 --> 50 | Trial primary completion date: Nov 2015 --> Nov 2014 N=100 --> 133 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Jul 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Metastases: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=165, Terminated, Sponsor: Merck KGaA
N=100 --> 133 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Jul 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period. N=100 --> 165 | Recruiting --> Terminated | Trial primary completion date: Apr 2014 --> Jul 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period.
- || REGN1400 / Regeneron
Enrollment closed, Trial primary completion date, Combination therapy: Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer (clinicaltrials.gov) - Nov 11, 2014
P1, N=59, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=100 --> 165 | Recruiting --> Terminated | Trial primary completion date: Apr 2014 --> Jul 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Nov 11, 2014
P1, N=13, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, Metastases: EMR062202-539: A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Nov 10, 2014
P=N/A, N=88, Terminated, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014 N=200 --> 88 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Jun 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Surgery: Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer (clinicaltrials.gov) - Nov 10, 2014
P2, N=19, Completed, Sponsor: Dana-Farber Cancer Institute
N=200 --> 88 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Jun 2013; The study was discontinued due to slow recruitment and subjects not completing follow up period. Active, not recruiting --> Completed | N=39 --> 19
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date: Pharmacokinetics and Metabolic Activation of Capecitabine (clinicaltrials.gov) - Nov 4, 2014
P2, N=24, Active, not recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Active, not recruiting --> Completed | N=39 --> 19 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Nov 4, 2014
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014 Trial primary completion date: Sep 2014 --> Oct 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy: Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (clinicaltrials.gov) - Nov 4, 2014
P1, N=21, Recruiting, Sponsor: Lund University Hospital
Trial primary completion date: Sep 2014 --> Oct 2016 Trial primary completion date: Jul 2014 --> Jul 2015
- | Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial: Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - Nov 4, 2014
P1, N=18, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Oct 30, 2014
P2, N=46, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Sep 2016 --> Sep 2017
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, WNT974 / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
New P1/2 trial, Combination therapy, Metastases: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (clinicaltrials.gov) - Oct 30, 2014
P1/2, N=60, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P1 trial, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Oct 28, 2014
P1, N=22, Not yet recruiting, Sponsor: Julie E. Bauman, MD, MPH
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Oct 28, 2014
P2, N=46, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 27, 2014
P1/2, N=42, Active, not recruiting, Sponsor: Ahmad Wehbe
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Oct 27, 2014
P2, N=33, Active, not recruiting, Sponsor: Ahmad Wehbe
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 22, 2014
P2, N=70, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: TPExtreme: Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC (clinicaltrials.gov) - Oct 20, 2014
P2, N=416, Recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 17, 2014
P2, N=245, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2008 --> Dec 2012
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Oct 15, 2014
P1, N=24, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2008 --> Dec 2012 Trial primary completion date: Jul 2015 --> Jul 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 15, 2014
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Combination therapy, Metastases: MLN8237 in Head and Neck Cancer (clinicaltrials.gov) - Oct 15, 2014
P1, N=9, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Feb 2014
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial suspension, Metastases: SWOG S0819: S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 11, 2014
P3, N=1546, Suspended, Sponsor: Southwest Oncology Group
Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Feb 2014 Recruiting --> Suspended
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum (clinicaltrials.gov) - Oct 11, 2014
P2, N=238, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Suspended Phase classification: P3 --> P2
- || Stivarga (regorafenib) / Bayer
Trial primary completion date, Combination therapy, Metastases: Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) - Oct 10, 2014
P1, N=54, Recruiting, Sponsor: Bayer
Phase classification: P3 --> P2 Trial primary completion date: Aug 2015 --> Nov 2015
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
New P2 trial, Metastases: Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab (clinicaltrials.gov) - Oct 10, 2014
P2, N=80, Active, not recruiting, Sponsor: Mayo Clinic
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 10, 2014
P2, N=30, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Aug 2015 --> Nov 2015 Trial primary completion date: Aug 2014 --> Aug 2015
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 10, 2014
P2, N=113, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Aug 2014 --> Aug 2015 Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (clinicaltrials.gov) - Oct 2, 2014
P2, N=51, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Nov 2014 --> Nov 2015
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PD(L)-1 Biomarker, IO biomarker, Metastases: Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) (clinicaltrials.gov) - Oct 2, 2014
P2, N=150, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, motolimod (VTX 2337) / BMS
Biomarker, Enrollment open, PD(L)-1 Biomarker: A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (clinicaltrials.gov) - Oct 2, 2014
P1, N=15, Recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Trial primary completion date: Nov 2014 --> Nov 2015 Not yet recruiting --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 28, 2014
P2, N=140, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Phase classification: P1/2 --> P1
- Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy (clinicaltrials.gov) - Sep 22, 2014
P2, N=147, Recruiting, Sponsor: Pam Cogliano
Phase classification: P1/2 --> P1 Suspended --> Recruiting
- Halaven (eribulin mesylate) / Eisai, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer (clinicaltrials.gov) - Sep 19, 2014
P1/2, N=63, Recruiting, Sponsor: howard safran
Suspended --> Recruiting Trial primary completion date: Aug 2014 --> Dec 2014
- luminespib (AUY922) / Ligand, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2014
P1, N=18, Recruiting, Sponsor: Swedish Medical Center
Trial primary completion date: Aug 2014 --> Dec 2014 Trial primary completion date: Feb 2014 --> Nov 2014